#China #Suzhou #Innovent #IBI363 #TAK-928

Long-Term Follow-Up Results for IBI363 Presented at ASCO 2026

Innovent Biologics, Inc. recently unveiled the long-term follow-up data for IBI363, a groundbreaking bispecific fusion protein, during the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. This innovative therapy targets non-small cell lung cancer (NSCLC) that exhibits resistance to immunotherapy. The results show promising overall survival benefits, showcasing IBI363’s potential to transform treatment outcomes for patients facing limited options.

Overview of the Study

The presented data comes from the Phase 1 proof-of-concept (PoC) study conducted in China, which evaluated the efficacy and safety of IBI363 monotherapy in patients with advanced NSCLC resistant to immunotherapy. A total of 136 patients were enrolled, and the findings indicated a significant survival rate across various demographics and conditions.

Robust Survival Benefits in Squamous NSCLC

Among the 67 patients with squamous NSCLC, none had known mutations in the EGFR gene. Patients received varying doses of IBI363, with those in the 3 mg/kg dose group showing remarkable improvement. The median progression-free survival (PFS) was reported at 10.1 months, while the median overall survival (OS) reached 18.2 months. Notably, 47.8% of patients remained alive after 24 months, providing a strong indication of IBI363’s long-term benefits in this challenging patient population.

Impacts on Adenocarcinoma Patients

The results were similarly compelling for patients with wild-type adenoNSCLC, where 58 subjects were treated with IBI363. In the cohort receiving the 3 mg/kg dose, the median PFS was recorded at 4.2 months and the median OS at 15.2 months. Importantly, survivors with a history of smoking exhibited enhanced outcomes, achieving a median OS of 23.4 months compared to their non-smoking counterparts.

Safety Profile Assessment

The safety profile for IBI363 remained encouraging throughout the study. In the overall population, 30.6% of individuals treated with the lower doses and 64.9% of those on the 3 mg/kg regimen experienced treatment-emergent adverse events (TEAEs) classified as grade 3 or higher. Despite this, the adverse events were manageable. The most common were arthralgia, anemia, and rash, which were primarily mild to moderate in severity. Importantly, no new safety signals were identified during the trial.

Expert Opinions on IBI363's Potential

The implications of these findings were echoed by Professor Jianya Zhou from the First Affiliated Hospital, School of Medicine, Zhejiang University. He emphasized the critical need for novel treatment options for patients who have continued disease progression following immunotherapy. IBI363’s dual mechanism, providing both immune checkpoint blockade and cytokine agonism, indicates it may induce durable responses in those with limited therapeutic avenues.

Furthermore, Dr. Hui Zhou, Chief RD Officer at Innovent, expressed optimism regarding IBI363’s potential as a treatment option. The positive short-term disease control results and verified long-term survival benefits could mark a pivotal shift in managing NSCLC resistant to immunotherapy.

Future Prospects

IBI363 is currently undergoing further rigorous testing, including a global Phase 3 clinical study named MarsLight-11 for squamous NSCLC, slated to address wider populations resistant to immunotherapy. This ongoing commitment to research reflects Innovent's dedication to tackling one of the most devastating cancers globally.

In conclusion, the long-term follow-up data presented by Innovent at ASCO 2026 highlights IBI363’s promising role in treating immunotherapy-resistant lung cancer. As this biopharmaceutical company continues to advance its clinical trials, the hope is to offer patients in dire need a viable therapeutic option that fosters both improved outcomes and quality of life.